Indivior

DB:2IVB

ABD / Sağlık Hizmetleri / İlaç

Genel Bakış

Haberler

10 Yıllık Finansal Veriler

Hisse Fiyatı

8,75 EUR


Key Metrics	Latest
Total Revenue	1,188 B
Adjusted EBITDA	316 M
EBITDA Margin	26,6%
Net Profit Margin	16,1%
Total Assets	1,466 B
Total Debt	374 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	1,014	1,058	1,093	1,005	785	647	791	901	1,093	1,188	1,188
% Growth		4.3%	3.3%	-8.1%	-21.9%	-17.6%	22.3%	13.9%	21.3%	8.7%

Adjusted EBITDA	409	399	199	341	214	101	199	228	277	316	316
% Margin	40.3%	37.7%	18.2%	33.9%	27.3%	15.6%	25.2%	25.3%	25.3%	26.6%	26.6%

Adjusted EBIT	377	387	193	332	202	88	187	215	260	292	292
% Margin	37.2%	36.6%	17.7%	33.0%	25.7%	13.6%	23.6%	23.9%	23.8%	24.6%	24.6%

Adjusted Net Income	251	211	68	305	153	38	192	175	203	192	192
% Margin	24.7%	20.0%	6.3%	30.3%	19.5%	5.8%	24.3%	19.4%	18.5%	16.1%	16.1%

Adjusted Basic EPS	1.75	1.47	0.47	2.09	1.05	0.26	1.32	1.26	1.48	1.45	1.45

Destekleyen Hesaplamalar

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Restated
USD	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	1,014	1,058	1,093	1,005	785	647	791	901	1,093	1,188	1,188
% Growth	NA	4.3%	3.3%	-8.1%	-21.9%	-17.6%	22.3%	13.9%	21.3%	8.7%

Cost of Revenue	(97)	(96)	(104)	(128)	(140)	(92)	(127)	(151)	(186)	(209)	(209)
Gross Profit	917	962	989	877	645	555	664	750	907	979	979
% Revenue	90.4%	90.9%	90.5%	87.3%	82.2%	85.8%	83.9%	83.2%	83.0%	82.4%	82.4%

Research and Development	(148)	(119)	(89)	(91)	(53)	(40)	(52)	(74)	(106)	(142)	(142)
Selling and Marketing	0	0	0	0	0	0	0	(52)	0	0	0
General and Admin	(408)	(456)	(707)	(478)	(390)	(427)	(425)	(417)	(543)	(588)	(588)
Other Inc / (Exp)	(15)	(238)	(14)	(16)	(26)	(251)	20	(287)	(270)	(283)	(283)
Total Operating Exp	(571)	(813)	(810)	(585)	(469)	(718)	(457)	(830)	(919)	(1,013)	(1,013)

Operating Income	346	149	179	292	176	(163)	207	(80)	(12)	(34)	(34)
% Revenue	34.1%	14.1%	16.4%	29.1%	22.4%	-25.2%	26.2%	-8.9%	-1.1%	-2.9%	-2.9%

Interest Expense	(61)	(51)	(42)	(14)	4	(10)	(17)	(8)	13	(9)	(9)
Pre-tax Income	285	98	137	278	180	(173)	190	(88)	1	(43)	(43)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	(57)	(63)	(79)	(3)	(46)	25	15	44	1	(5)	(5)
Net Income to Company	228	35	58	275	134	(148)	205	(44)	2	(48)	(48)
% Margin	22.5%	3.3%	5.3%	27.4%	17.1%	-22.9%	25.9%	-4.9%	0.2%	-4.0%	-4.0%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	228	35	58	275	134	(148)	205	(44)	2	(48)	(48)

Preferred Dividends	0	0	0	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0	0	0	0

Net Income to Common	228	35	58	275	134	(148)	205	(44)	2	(48)	(48)
% Margin	22.5%	3.3%	5.3%	27.4%	17.1%	-22.9%	25.9%	-4.9%	0.2%	-4.0%	-4.0%

As Reported
Basic EPS (Continuing Ops)	1.59	0.24	0.40	1.89	0.92	(1.01)	1.41	(0.32)	0.01	(0.36)	(0.36)
Diluted EPS (Continuing Ops)	1.55	0.24	0.40	1.85	0.90	(1.01)	1.35	(0.32)	0.01	(0.36)	(0.36)

WA Basic Shares Out.	143.72	143.98	144.23	145.43	146.05	146.57	145.66	139.00	137.31	132.31	132.31
WA Diluted Shares Out.	146.62	148.64	149.70	150.23	151.07	146.57	151.94	139.00	141.80	132.31	132.31

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	285	98	137	278	180	(173)	190	(88)	1	(43)	(43)
Addback: Net Interest Expense	61	51	42	14	(4)	10	17	8	(13)	9	9
Addback: Other Non Operating Expenses, Total	0	0	0	0	0	0	(3)	(1)	1	2	2
Addback: Depreciation & Amortization	32	12	6	9	12	13	12	13	17	24	24
Addback: Restructuring Charges	0	0	0	13	20	11	(1)	0	0	61	61
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0	22	4	4
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	9	9
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	(20)	0	0	0	0
Addback: Asset Writedown	16	0	0	24	0	0	0	0	0	35	35
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	(12)	0	(1)	(1)	(1)
Addback: Legal Settlements	0	220	0	40	10	235	14	296	247	200	200
Addback: Other Unusual Items	15	18	14	(37)	(4)	5	2	0	3	16	16
Adjusted EBITDA	409	399	199	341	214	101	199	228	277	316	316
% Margin	40.3%	37.7%	18.2%	33.9%	27.3%	15.6%	25.2%	25.3%	25.3%	26.6%	26.6%

Adjusted EBIT	377	387	193	332	202	88	187	215	260	292	292
% Margin	37.2%	36.6%	17.7%	33.0%	25.7%	13.6%	23.6%	23.9%	23.8%	24.6%	24.6%

Adjusted Net Income Reconciliation
Net Income to Company	228	35	58	275	134	(148)	205	(44)	2	(48)	(48)
Addback: Unusual Items	31	238	14	40	26	251	(17)	296	271	324	324
Less: Tax Benefit of Unusual Items (26%)	(8)	(62)	(4)	(10)	(7)	(65)	4	(77)	(70)	(84)	(84)
Adjusted Net Income	251	211	68	305	153	38	192	175	203	192	192
% Margin	24.7%	20.0%	6.3%	30.3%	19.5%	5.8%	24.3%	19.4%	18.5%	16.1%	16.1%

Yüklenme Hatası

Indivior

DB:2IVB

ABD / Sağlık Hizmetleri / İlaç

10 Yıllık Finansal Veriler